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Sununary A study of cancer incidence in a cohort of 597 women with Turner syndrome (TS) and a virtually
complete follow-up is presented. The cohort was established from the Danish Cytogenetic Register.
Information on cancer incidence was obtained from the Danish Cancer Registry and compared with the
expected number calculated from the age-, period- and site-specific cancer rates for Danish women. A total of
21 neoplasms was observed, of which 13 occurred more than 1 year after diagnosis of TS, corresponding to a
relative risk of cancer of 1.1. Wilms' tumour was the only identified childhood cancer. No case of
gonadoblastoma or dysgerminoma was identified in the 29 women with a Y chromosome or in the women in
whom no Y chromosome material was detected by standard cytogenetic methods, suggesting that the risk of
ovarian germ cell tumours may be lower than previously estimated. Colon cancer was observed in five patients
(relative risk 6.9, 95% confidence interval 2.2-16.2). Further studies are needed to assess whether colon cancer
in TS is related to Turner-associated genes on the sex chromosome(s).
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Turner syndrome (TS) is due to partial or complete
monosomy of the X chromosome in a female. The clinical
features include short stature, neck webbing, primary
amenorrhoea and sterility. Structural kidney abnormalities,
cardiovascular and skeletal anomalies are frequently asso-
ciated features. TS is found in approximately 1 in 2100
newborn girls (Nielsen and Wohlert, 1991).
A British study of 156 females with TS who had survived
infancy found a mortality rate four times the expected, but
only one of the 15 deaths in this rather young cohort was
attributed to cancer (Price et al., 1986). However, there has
been some concern about a possibly increased risk of
gynaecological tumours due to prolonged oestrogen therapy
(Wertelecki et al., 1970; Clement and Young, 1987) or of
hepatocellular carcinoma due to progestagen therapy
(Watanabe et al., 1994).
The probability that gonadoblastoma or dysgerminoma
arises in women with dysgenetic gonads in the presence of Y
chromosome material has been estimated to be 30% (Verp
and Simpson, 1987), and early prophylactic oophorectomy
has been recommended (Troche and Hernandez, 1986).
TS has been reported anecdotally in association with a
variety of neoplasias (Lewis et al., 1963; Pawliger et al., 1970;
Wertelecki and Shapiro, 1970; Wertelecki et al., 1970; Gare et
al., 1993; Say et al., 1971; Siegler, 1975; Louka et al., 1978;
Chaganti et al., 1982; Andreev and Zlatkov, 1971; Cheng and
Tsai, 1993; Males and Lain, 1972; Olson et al., 1995),
including multiple primary cancers (Herrera Ornelas et al.,
1984; Ochi et al., 1985). No conclusion can be drawn from
these data, and publication bias may over-emphasise
coincidental findings, as shown recently for Klinefelter
syndrome (Hasle et al., 1995). There are no available cohort
studies of the relative risk of cancer in women with TS.
We present the cancer occurrence in a group of 597
women with TS and a virtually complete follow-up.
Material and methods
The study cohort
The Danish Cytogenetic Register was founded in 1968 and
has since collected information on constitutional chromoso-
mal abnormalities from cytogenetic laboratories throughout
Denmark (Nielsen, 1980). Abnormalities diagnosed before
the start of the register in 1968 have also been included in the
register, and it is assumed that it has a virtually complete
coverage of the constitutional chromosomal abnormalities
diagnosed in Denmark since 1961 (Nielsen, 1980).
A total of 608 women with a diagnosis of TS were
registered in the Cytogenetic Register by December 1994.
Eleven persons were excluded from the cohort for the
following reasons: residence in Greenland (n =4), date of
birth after 31 December 1992 (n =6) or death on day of birth
(n = 1). Accordingly, the final study cohort consisted of 597
women with TS.
Follow-up procedures
Information on vital status and emigration was obtained by
linkage to the Danish Central Population Register using the
personal identification number, unique to every resident in
Denmark. One person died before the introduction of the
personal identification number in 1968 but was identified
through the National Death Certificate File. Thus, follow-up
data were obtained for the entire cohort.
Information on cancer incidence was obtained from the
Danish Cancer Registry, which has received notifications on
malignant diseases from all clinical and pathological
departments in the country since 1943. The notifications to
the registry are supplemented by a scrutiny of all death
certificates. The registry is considered to have a practically
complete coverage of the occurrence of cancer in Denmark
(Storm, 1988). All cases of ambiguous or unusual cancer
notification in the cohort were verified by a review of the
clinical and pathological data from the hospital where the
patient had been treated.
All cancers occurring in the cohort since 1943 were sought
in the Cancer Registry. However, person-years at risk for
the calculation of relative risk of cancer were counted from 1
year after the cytogenetic diagnosis until date of death,
emigration or 31 December 1992, whichever occurred first.
Statistical analyses
The site-specific cancer incidence in the study cohort was
compared with the expected incidence, which was calculated
from the 5 year age- and period-specific rates for all Danish
women. The relative risk was calculated as the ratio of the
observed vs the expected number. The statistical evaluation
was based on the calculation of95% confidence intervals (CI)
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on the assumption that the observed number follows a
Poisson distribution. If the CI excludes the value of 1, the
relative risk is considered to be significantly different from 1.
Results
Characteristics of the women
The year of birth, the year of cytogenetic examination and
the age at cytogenetic examination of the 597 women with TS
are shown in Table I. The number of women with
cytogenetically diagnosed TS was relatively low in the early
1960s, but has remained fairly stable from 1970 onwards,
with about 20 new cases each year. Most of the women were
diagnosed in childhood or adolescence (median age at
diagnosis 15 years, mean 20 years).
The karyotypes are shown in Table II. A 45,X karyotype
was found in 291 (49%) cases, 263 (44%) cases had
mosaicism and 43 (7%) cases had structural abnormalities.
Y chromosome material was detected in 29 patients.
All observed cancers
All observed cancer cases are shown in Table III. A total of
21 neoplasms was observed in 20 women. One woman had
breast cancer at the age of 74 and papillary cystadenocarci-
noma of the ovary at the age of 91. The median age at cancer
diagnosis was 55 years (range 7-91). Eight of the 20 women
had a 45,X karyotype and 12 had mosaicism. None of the
cases had cytogenetically detected Y material. Prostate
adenocarcinoma occurred in one woman, as reported in
detail previously (Svanholm et al., 1987). The single case of
liver neoplasm was a metastasis from an adenocarcinoma of
unknown primary site.
Relative risk of cancer
The observed and expected numbers of site-specific cancer
cases are shown in Table IV. Only cancer cases which
occurred more than 1 year after the diagnosis of TS were
included in this analysis of relative risk. A total of 13
neoplasms was observed during this period compared with
11.4 expected, yielding a relative risk of 1.1 (95% CI 0.6-
2.0). Five cases of colon cancer (relative risk 6.9, 95% CI
2.2-16.2) were observed.
Discussion
A Danish study of systematic chromosome examinations of
34 900 consecutive liveborn infants found TS in 1 out of
every 2100 newborn girls (Nielsen and Wohlert, 1991),
corresponding to about 16 girls with TS born each year in
Denmark. The cytogenetically recognised cases of TS in
Denmark correspond to 13 cases per year of birth for those
born in 1950-79 (Table I), and hence represent most of the
expected number. In contrast, only two cases per year of
birth were cytogenetically diagnosed in women born in
1910-1939. Thus, among elderly women with TS, among
whom the expected number of cancers is highest, the cohort
is not representative of all women with TS, but only of the
minority which was confirmed cytogenetically.
The cohort consists of women with cytogenetically
diagnosed TS. The karyotype analysis has only been
available from 1961. The cancer occurrence has been
followed from 1943 onwards. The design implies a risk of
selection bias during the first decades of the observation
period because only persons who survived until the era when
cytogenetic analyses became available would be included in
the cohort, resulting in an underestimation of, particularly,
Table I Demographic characterisations of the 597 women with Turner syndrome. The date of examination was missing in three persons
Year of birth Number Year of examination Number Age at examination Number
Before 1899 4 1961-65 30 0-4 96
1900-09 7 1966-70 67 5-9 47
1910- 19 18 1971 -75 107 10-14 138
1920-29 24 1976-80 108 15-19 123
1930-39 19 1981-85 96 20-24 40
1940-49 71 1986-90 117 25-29 33
1950-59 112 1991 -94 69 30-39 36
1960-69 145 40-49 31
1970-79 121 50-59 24
1980-89 59 60-82 26
1990-92 17
Table II Karyotypes in the 597 women with Turner syndrome
Simple monosomy X 49%
45,X 291
Mosaicism 44%
45,X/46,XX 90
45,X/46,X,i(Xq); 46,XX/46,X,i(Xq) 45
45,X/46,X,del(Xp); 46,XX/46,X,del(Xq); 45,X/46,X,r(X) 37
45,X/46,X,mar(X); 45,X/46,XX/46,X,mar(X) 16
45,X/46,XX/47,XXX; 45,X/47,XXX; 45,X/46,XX/47,XXX/48,XXXX/49,XXXXX 34
45,X.46,X,t(X;Va) 4
45,X/46,X, +mar; 46,X +mar/47,XX, + mar 9
45,X/46,XY; 45,X/46,X,mar(Y) 28
Structural abnormalities 7%
46,X,i(Xq) 20
46,X,i(Yq) 1
46,X,del(Xp); 46,X,del(Xq) 14
46,X,mar(X) 6
46,X,t(X;Va) 2
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Table III Observed cancer cases in the 597 women with Turner syndrome (TS), with date of TS diagnosis, date of cancer diagnosis, age at
cancer diagnosis and karyotype
Site/histology
a Caecum/adenocarcinoma
a Ascending colon/adenocarcinoma
a Transverse colon/adenocarcinoma
a Sigmoid colon/adenocarcinoma
a Sigmoid colon/adenocarcinoma
Rectum/adenocarcinoma
a Liver/adenocarcinoma metastasis
a Lung/adenocarcinoma
a Breast/ductal carcinoma
Breast/ductal carcinoma
Breast/ductal carcinomab
a Breast/no histology
a Ovary/cystadenocarcinomab
a Vulva/carcinoma
Female prostate/adenocarcinoma
Kidney/Wilms' tumour
a Skin/basal cell carcinoma
Skin/basal cell carcinoma
a Skin/basal cell carcinoma
Skin/basal cell carcinoma
Acute myeloid leukaemia
ICD-7
153.5
253.0
253.1
253.3
253.3
154.0
156.0
162.4
170.1
170.2
170.2
170.2
175.2
176.0
176.9
480.1
191.3
191.3
191.5
191.8
214.1
TS date
1/66
12/67
7/81
6/63
3/69
1/94
11/75
7/86
10/76
7/83
3/63
11/66
3/63
2/64
11/85
6/93
3/71
7/83
9/75
6/76
9/67
a Cancer occuring more than 1 year after diagnosis ofTS. b Same patient.
Cancer date Cancer age
5/92
8/84
9/88
9/66
7/77
12/78
7/90
4/91
1/86
4/83
4/59
10/81
6/76
6/84
10/85
2/88
1/83
4/79
10/82
6/76
8/67
55
64
90
49
40
42
77
47
58
54
74
81
91
35
74
7
49
48
58
65
46
Karyotype
45,X
45,X
45,X/46,XX
45,X
45,X
45,X/46,XX
45,X/46,XX
45,X/46,XX
45,X/46,XX/47,XXX
46,X+mar/47,XX+mar
45,X/46,XX/46,X,mar(X)
45,X/46,XX/47,XXX
45,X/46,XX/46,X,mar(X)
45,X
45,X/46,XX/46,X,t(X;13)
45,X/46,XX
45,X/46,X,i(Xq)
45,X
45,X
45,X
45,X/46,XX
Table IV Observed and expected site-specific number of cancer cases in women with Turner syndrome. Only cancers that occurred more than
1 year after the diagnosis of Turner syndrome were included
Site (ICD-7)
All sites (140-205)
Buccal cavity (140-148)
Digestive system (150-159)
Colon (153)
Liver (156)
Respiratory system (160 - 164)
Lung (162)
Breast (170)
Female genital organs (171 - 176)
Ovary (175)
Other (176)
Urinary tract (180-181)
Skin (190-191)
Non-melanoma (191)
Other specified sites (192-197)
Secondary and unspecified sites (198-199)
Lymphatic and haematopoietic tissue (200-205)
Observed
13
0
6
S
2
2 1
2
2
1
1
0
2
2
0
0
0
Expected
11.40
0.13
1.85
0.72
0.05
0.75
0.67
2.67
2.07
0.57
0.09
0.44
1.81
1.27
0.74
0.24
0.70
Relative risk
1.1
3.2
6.9
19.3
1.3
1.5
0.7
1.0
1.8
11.7
95% CI
0.6-2.0
1.2-
2.2-
0.3-
0.0 -
0.0-
0.1 -
0.2-
0.1 -
0.2-
1.1
1.6
-7.1
-16.2
-107.3
-7.4
-8.3
-2.5
-3.2
-8.7
-65.2
0.1 -4.0
0.2-5.7
the tumours with a high mortality rate. On the other hand,
patients with cancer undergo a large number of investiga-
tions, which might introduce a surveillance bias, resulting in a
higher rate of recognised TS in those women who develop
cancer. In the present study, four women had TS diagnosed
shortly after the cancer diagnosis. To eliminate the two types
of selection bias (cancer diagnosed without the recognition of
TS and TS diagnosed as a result of the cancer diagnosis) the
calculations of relative risk were performed by counting
person-years at risk and observed cancers only from 1 year
after the cytogenetic diagnosis of TS.
TS is not always diagnosed in prepubertal girls because of
the paucity of clinical manifestations. Therefore, TS is likely
to be diagnosed mainly in girls who survive a childhood
cancer and may even then be overlooked because infertility
may be considered therapy related. Consequently, the present
study has an inherent risk of overlooking cases of childhood
cancer. We identified only one case of childhood tumour, a
case of Wilms' tumour adding to previous studies suggesting
a causal association between TS and Wilms' tumour (Say et
al., 1971; Olson et al., 1995). This association may be related
to the increased frequency of renal malformations among
children with Wilms' tumour (Olson et al., 1995),
although no evidence of any renal malformation was
detected in our case.
The probability that gonadoblastoma or dysgerminoma
arises in women with dysgenetic gonads in the presence of Y
chromosome material has been estimated to be 30%. (Verp
and Simpson, 1987), and early prophylactic oophorectomy
has been recommended (Troche and Hernandez, 1986).
Cryptic mosaicism for at least part of the Y chromosome
may be present in a significant number of the women without
cytogenetically detected Y chromosome (Kocova et al., 1993;
Coto et al., 1995), implying a potentially increased risk of
gonadal tumours. We did not identify any cases of
gonadoblastoma or dysgerminoma in the 29 women with a
Y chromosome or in the remaining 568 women in whom no
Y chromosome material was detected by standard cytogenetic
methods. We have no data on the number of women with Y
chromosome material who had an oophorectomy. The mean
age at cytogenetic diagnosis in these women was 18 years
(median 16 years), implying that at least half the women went
through adolescence without oophorectomy. The mean age at
the time of diagnosis of germ cell tumours in women with Y
material was 18 years in 133 reported cases (Troche and
Hernandez, 1986). We did not observe germ cell tumours in
any of the women, indicating that the risk of ovarian germ
cell tumours may be lower than previously estimated.
We observed a statistically significant increase in the risk
of colon cancer (relative risk 6.9). An association between TS
and colon cancer has occasionally been reported previously
(Herrera Ornelas et al., 1984; Ochi et al., 1985; Cheng andCancer occwrnt hi Turner syix*ome
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Tsai, 1993). TS is associated with an increased risk of
ulcerative colitis (Knudtzon and Svane, 1988), which in itself
is associated with an increased risk of colorectal cancer
(Mellemkjaer et al., 1995). However, a review of the medical
charts of the present cases did not identify any with chronic
inflammatory diseases. The apparent association between TS
and colon cancer needs further studies of the possible
pathogenic mechanisms.
Two autosomal dominant inherited conditions associated
with colon cancer are known: familial adenomatous polyposis
of the colon (APC) and hereditary non-polypous colon
cancer (HNPCC). APC is caused by germilne mutations in a
tumour-suppressor gene on chromosome 5 (Bodmer et al.,
1987), whereas HNPCC is caused by germline mutations in
genes encoding specific DNA repair enzymes (Fishel et al.,
1993). Mutations of these repair genes are associated with a
dramatically increased frequency of mutations all over the
genome. A similar mutator phenotype is observed in many
sporadic colon tumours, and it is believed that these colon
cancers are caused by a highly increased risk for secondary
mutations activating specific proto-oncogenes and/or inacti-
vating specific tumour-suppressor genes.
The Turner phenotype is probably the result of the loss of
one functional copy of one or more genes common to the X
and Y chromosomes, the X-linked copies escaping X
inactivation. Among the candidates are the genes encoding
ribosomal protein S4, RPS4Y and RPS4X (Fisher et al.,
1990). Analyses of the mutator phenotype in colon tumours
from TS patients are necessary to assess whether colon cancer
in TS may provide a potential link to Turner-associated genes
on the sex chromosome(s).
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